Hybrid Imaging Market

The global hybrid imaging market was valued at USD 5.615 billion in 2025 and is estimated at USD 5.828 billion in 2026. Revenue is projected to reach USD 7.849 billion by 2034, representing a 3.8% CAGR during 2026–2034.

Hybrid imaging combines radiotracer-based functional measurements with anatomical information in one coordinated examination. PET/CT, SPECT/CT and PET/MR are included where a single integrated platform produces registered molecular and structural images. The revenue boundary covers new clinical and preclinical scanners, dedicated reconstruction software supplied with those systems, installation and manufacturer service contracts. Standalone CT, MRI and PET-only devices, radiopharmaceutical doses, patient scan fees and independent interpretation services are outside the measured equipment market.

The International Agency for Research on Cancer counted 20.6 million new cancer cases worldwide in 2024 and projected 34.4 million annually by 2050. PET/CT provides metabolic staging and response information in oncology, while SPECT/CT localizes tracer uptake in bone, endocrine and radionuclide-therapy pathways. Hospitals are therefore buying systems that can handle conventional nuclear medicine and emerging targeted-radiopharmaceutical protocols. The 2026 equipment forecast grows more slowly than the number of scans because replacement cycles, site preparation and service capacity constrain annual installations.

Digital detector architecture influences hospital procurement specifications through measurable timing and sensitivity performance. Siemens Healthineers received U.S. clearance for Biograph Trinion in June 2024, citing 239-picosecond time-of-flight performance and a compact air-cooled design. GE HealthCare obtained European CE marking for the 128-centimeter Omni total-body PET/CT in November 2025, emphasizing head-to-thigh imaging in one bed position. Siemens and GE caution that measured scanner performance depends on detector configuration, tracer dose and reconstruction settings. Equipment buyers compare throughput gains against the cost of detector upgrades and construction.

Simultaneous PET/MR remains a specialist category because magnetic resonance infrastructure, attenuation correction and interpretation require more resources than conventional PET/CT. United Imaging announced European CE marking for its uPMR Zenith in September 2026 with a targeted 15-minute whole-body patient slot. Siemens received U.S. clearance for its Biograph One PET/MR in January 2026, expanding the clinical options available for combined molecular and soft-tissue imaging. Adoption is concentrated in major academic hospitals, pediatric oncology programs and neuroscience centers rather than routine outpatient facilities.

Source: IARC global cancer statistics; Siemens Biograph Trinion clearance; GE Omni 128 cm CE marking; United Imaging uPMR Zenith CE marking.

The study tracks integrated clinical and preclinical hybrid scanners, manufacturer-linked software and service revenue, allocating each system once across four independent segmentation dimensions.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 3.8% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Oncology workload sustains replacement demand for integrated PET/CT systems

IARC estimated 20.6 million new cancer diagnoses in 2024, including about 2.6 million lung cancers. PET/CT supports staging, radiotherapy planning and response assessment for many malignancies, while hybrid SPECT/CT is useful for skeletal and radionuclide-therapy pathways. This clinical workload gives large hospitals a reason to replace aging equipment before the end of its physical life. However, capital approval is still tied to utilization forecasts, isotope supply, radiologist availability and whether local payers reimburse the intended examination.

Digital detectors increase throughput without proportionate new room capacity

Siemens reported 239 ps time-of-flight performance for Biograph Trinion in 2024, and GE described a 128 cm total-body PET/CT configuration in 2025. Higher sensitivity can shorten acquisition, lower administered activity or improve image quality, depending on protocol. The commercial effect is strongest at centers that cannot add another scanner room but can extend daily appointments through faster acquisitions. Detector upgrades nevertheless require clinical validation, workflow training and compatible service arrangements, so conversion from older systems proceeds over multiple purchasing cycles.

Theranostic expansion raises demand for quantitative SPECT/CT and PET/CT

GE HealthCare and University Hospital Essen opened a nuclear medicine center in June 2026 with StarGuide GX SPECT/CT and Omni PET/CT systems. Mediso installed a TheraMAX SPECT/CT at Heidelberg University Hospital in October 2025 for imaging radionuclide therapies. Such programs need repeatable tracer quantification and dose assessment rather than only lesion localization. Demand is concentrated in centers with radiopharmacy access, oncology coordination and radiation-protection expertise, making specialized SPECT/CT a differentiated purchase alongside mainstream PET/CT. Such departments often require both platforms to manage patient selection and treatment-response studies.

Capital budgets and skilled staffing limit equipment deployment

Hybrid scanners require radiation-shielded rooms, trained technologists, nuclear medicine physicians, medical physicists and reliable radiotracer delivery. The IAEA NUMDAB platform documents uneven availability of PET, SPECT and hybrid infrastructure between countries. Facilities also face maintenance contracts, detector calibration, CT tube replacement and software validation after installation. These costs particularly affect independent imaging centers and smaller public hospitals, which may defer upgrades or purchase refurbished equipment when clinical demand is insufficient to support a new integrated platform.

Coverage rules and accreditation shape clinical utilization economics

U.S. Medicare Part B covers medically necessary PET and other diagnostic imaging, but outpatient coinsurance and accreditation requirements affect where scans can be billed. A hospital can justify a new scanner only if referring clinicians, tracers and reimbursement produce enough examinations to support fixed costs. In countries without predictable nuclear-medicine reimbursement, adoption is more dependent on research grants or tertiary-care budgets. Software-enabled workflow efficiency can improve operating economics, but it does not eliminate payer restrictions or the need for credentialed personnel.

Sources: IARC; Siemens Healthineers; GE HealthCare; Mediso; IAEA NUMDAB; Medicare.

Long-axial-field PET/CT expands single-bed acquisition

GE HealthCare announced CE marking for the 128 cm Omni total-body PET/CT in November 2025. United Imaging commissioned its uMI Panorama GS at Hannover Medical School in January 2026, highlighting long-field systems for clinical and translational work. Extended coverage allows dynamic imaging across more anatomy in one acquisition, improving kinetic research and selected high-throughput pathways. These systems command higher capital budgets, so adoption is initially concentrated in academic hospitals and high-volume oncology centers with radiotracer research and multidisciplinary treatment programs.

PET/MR platforms enter a new clinical generation

Siemens Healthineers received U.S. FDA clearance for Biograph One PET/MR in January 2026, while United Imaging secured European CE marking for uPMR Zenith in September 2026. Both systems integrate simultaneous molecular and magnetic resonance information, addressing soft-tissue characterization and neurological assessment. The economics remain different from PET/CT because magnet infrastructure and specialized interpretation raise operating requirements. Their growth depends on whether centers can schedule combined protocols that replace separate examinations and produce clinically actionable findings.

Quantitative software becomes integral to theranostic workflow

GE HealthCare reported U.S. clearance of MIM LesionID Pro in January 2026 for PSMA PET/CT and SPECT/CT tumor-burden analysis. Its MIM KineticID dynamic PET application remained 510(k) pending when announced in May 2026. Automated lesion mapping and kinetic modeling can support repeatable assessments, yet clinical deployment depends on validated indications and local software governance. Buyers increasingly evaluate integrated scanners together with segmentation, dosimetry and reconstruction capabilities rather than treating the hardware specification as the only procurement criterion.

Compact and mobile PET/CT opens selected outpatient opportunities

United Imaging presented the uMI Panvivo family at SNMMI 2026 with multiple cleared axial-field configurations and a mobile variant. Siemens Biograph Trinion uses an air-cooled design and embedded computing to reduce room requirements, while Positron markets NeuSight PET/CT for cardiology practices. Smaller installation footprints help centers that lack space for traditional utility rooms. Mobile deployment still requires tracer delivery, radiation licensing and patient scheduling, so it is most effective when shared across sites with dependable referral volumes.

SPECT/CT modernization follows radionuclide-therapy needs

GE HealthCare announced StarGuide GX as U.S. 510(k) pending in September 2026 after a European CE mark. Mediso introduced TheraMAX in October 2024 with detectors configured for radionuclides used in targeted therapy, including lutetium-177 and iodine-131. Spectrum Dynamics offers ring-shaped CZT VERITON-CT systems for quantitative SPECT imaging. These developments shift specifications from planar scintigraphy toward tomographic sensitivity, energy handling and repeatable quantitative measurements, supporting therapy planning and post-treatment monitoring at specialist nuclear medicine centers.

Hybrid systems register radiotracer uptake with CT or MR anatomy to improve localization and quantitative interpretation. PET/CT remains the routine oncology platform; SPECT/CT serves conventional nuclear medicine and radionuclide-therapy workflows; PET/MR adds soft-tissue information where MRI is clinically valuable.

PET/CT combines positron-emission information with X-ray localization and attenuation correction. Siemens cited 239 ps timing for its Trinion launch, while GE emphasizes long-field dynamic capability on Omni 128 cm. Procurement teams must evaluate actual site protocols because advertised timing, sensitivity and dose reductions are configuration dependent. In clinical oncology, a scanner that accommodates both FDG and disease-specific tracers can support wider referral networks without requiring a separate modality room.

SPECT/CT combines gamma-emission tomography with CT localization. Mediso TheraMAX uses detectors designed for radionuclide-therapy isotope energies, and Spectrum Dynamics VERITON-CT applies a ring of CZT detectors for tomographic studies. Quantitative accuracy, collimator choice and reconstruction correction are important for serial dosimetry. Sites introducing radioligand therapy often need both PET/CT for patient selection and SPECT/CT for follow-up measurements, so the two product categories can be complementary rather than direct substitutes.

PET/MR systems place PET detection within an MR-compatible environment to acquire metabolic and soft-tissue signals simultaneously. The Siemens Biograph One clearance and United Imaging Zenith CE mark in 2026 illustrate renewed vendor investment. Academic centers can use the modality for brain disorders and selected pediatric or pelvic tumors, but high operating complexity limits broad deployment. Preclinical laboratories also purchase hybrid PET/CT or PET/MR systems for tracer translation, with Bruker and MR Solutions providing dedicated small-animal platforms.

Type classification separates integrated PET/CT, SPECT/CT and PET/MR systems by the nuclear and anatomical modalities combined in one platform. PET/CT is the largest revenue category because it supports oncology, cardiology and neurological tracer studies in established hospital workflows.

The fastest technical innovation is occurring in long-field PET/CT and simultaneous PET/MR, while SPECT/CT continues to modernize around quantitative theranostics. Purchase decisions remain modality specific: a PET/MR installation rarely replaces a high-volume routine PET/CT service without a clear clinical protocol mix.

Applications are assigned by the primary clinical indication for which a hybrid scanner is contracted or predominantly used. Oncology is the largest category, followed by cardiology, neurology and orthopedics or other indications. Research-only scanners are classified by their principal experimental disease program.

Oncology remains the largest application through 2034, but neurology and radioligand-therapy monitoring are important sources of new protocols. Each system is assigned once to its principal clinical use rather than counted again for every examination it can perform.

End-user segmentation identifies the institution purchasing and operating the integrated equipment. Hospital nuclear medicine departments represent the largest group, while freestanding diagnostic imaging centers and academic research institutions follow distinct financing and utilization models.

Hospitals should retain leadership because most hybrid examinations require radiopharmaceutical handling and specialist interpretation. Diagnostic centers may gain access through compact systems, while research buyers contribute technology innovation but remain a smaller portion of overall market value.

The detector platform classifies each scanner by its principal nuclear detection hardware, avoiding overlap between AI software and physical detector technology. PET equipment is separated into digital silicon photomultiplier and conventional detector systems; SPECT equipment is divided into CZT and scintillation designs.

Detector modernization affects scanner economics through dose efficiency, acquisition time and software requirements. The classification measures equipment sold by hardware architecture, not the number of reconstruction algorithms or optional workflow applications installed on a system.

Regional demand depends on cancer referral volumes, nuclear medicine reimbursement, radiotracer distribution and investment in hospital imaging infrastructure. The 2025 regional shares allocate manufacturer equipment revenue, not the number of patient examinations or the burden of disease.

Equipment purchasing depends on clinical reimbursement, radiation licensing, specialist staffing and capital budgets. A scanner may offer excellent detector performance but remain underutilized if tracer distribution or referral pathways are weak.

Medicare describes PET, CT, MRI and nuclear medicine as covered diagnostic tests when medically necessary and ordered by a clinician. In independent facilities, advanced diagnostic imaging accreditation affects payment eligibility. These conditions encourage imaging centers to document expected referral volumes before purchasing a scanner. Hospital outpatient copayments and payer-specific medical necessity rules may influence how often a new device is used, even when equipment itself has regulatory clearance.

European CE marking of the Omni 128 cm and uPMR Zenith during 2025–2026 broadened the portfolio of systems available to hospitals. However, procurement also depends on capital allocation, isotope handling, staffing and service coverage. Research institutions also face competitive grant cycles, institutional ethics reviews and specialized animal-housing requirements. Academic research laboratories operate under different financing: Bruker PET/CT Si78 and MR Solutions modular PET/MR systems are purchased primarily for tracer translation and animal imaging rather than reimbursement-driven routine patient care. Institutions therefore compare lifetime instrument availability, tracer throughput and shared laboratory access before approving research purchases. Service uptime and access to qualified nuclear medicine physicists can determine whether the funded equipment supports longitudinal tracer studies.

Source: Medicare diagnostic imaging; GE Omni CE mark; United Imaging Zenith CE mark.

Hybrid imaging systems require jurisdiction-specific medical device authorization before commercial clinical deployment. A CE mark, FDA clearance or pending submission must not be treated as interchangeable commercial status.

The FDA describes the 510(k) pathway as a substantial-equivalence review for devices subject to premarket notification. Siemens explicitly announced clearance for Biograph Trinion and Biograph One, whereas GE described StarGuide GX as pending in September 2026. These differences matter for procurement schedules, since an investigational or pending configuration cannot be counted as marketed in a jurisdiction until its authorization is established.

United Imaging uPMR Zenith entered the European CE-marked portfolio in September 2026, while GE Omni 128 cm received CE marking in November 2025. Hospitals should still verify the exact detector, software and radiotracer configurations permitted in their countries. Regulatory availability creates a potential order pipeline, but installations depend on local tenders, acceptance testing and workforce readiness. Device approvals do not automatically extend to every optional reconstruction algorithm or radionuclide workflow. Sites should confirm the approved software version and intended use when evaluating upgrades to existing scanners. Post-installation quality assurance, radiation-safety reviews and physician training can affect the interval between a purchase order and the first clinical examination. Manufacturer claims for sensitivity and timing must be evaluated using the specific system configuration authorized for the intended indication.

The hybrid imaging market is led by diversified medical technology suppliers with broad service networks, alongside specialist SPECT/CT, cardiac PET/CT and preclinical instrument manufacturers. Competitive differentiation centers on detector sensitivity, integrated software, room footprint, installed-base support and clinical application coverage.

Siemens Healthineers highlighted 239 ps time-of-flight performance in its 2024 Trinion launch and received FDA clearance for Biograph One in January 2026. GE obtained a European CE mark for Omni 128 cm in 2025 and reported a 2026 Essen theranostics installation involving both PET/CT and SPECT/CT. Their ability to offer hardware, service and advanced reconstruction within a single contract appeals to hospitals with high scanner utilization and limited in-house engineering resources.

United Imaging is broadening access through scalable PET/CT systems and PET/MR innovation. Its 2025 interim report cited installations in Australia and orders in India, while the 2026 uPMR Zenith CE mark adds a new European configuration. Mediso and Spectrum Dynamics compete on quantitative SPECT/CT, including high-energy isotope protocols and ring-shaped detector geometry. In the preclinical segment, Bruker PET/CT Si78, MR Solutions modular PET platforms and MILabs instruments support tracer-development laboratories where reproducibility and animal handling are critical.

• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• Shanghai United Imaging Healthcare Co., Ltd.
• Koninklijke Philips N.V.
• Canon Medical Systems Corporation
• Mediso Medical Imaging Systems
• Spectrum Dynamics Medical
• Bruker Corporation
• Positron Corporation
• MR Solutions Ltd.
• MILabs B.V.

Hybrid imaging equipment revenue is forecast to rise from USD 5.828 billion in 2026 to USD 7.849 billion in 2034, a 3.8% CAGR. Demand is supported by oncology replacement cycles and theranostic expansion, while capital intensity prevents scanner sales from growing as quickly as clinical imaging volume.

PET/CT is expected to retain the largest revenue pool because its clinical role in oncology is supported by established referral pathways. Siemens Trinion and GE Omni demonstrate that future purchases will span compact high-throughput platforms and premium long-field systems. Hospitals will weigh acquisition time, dose efficiency and reconstruction capability against room constraints and long-term service costs. Faster scanners can increase utilization without requiring a proportional increase in technologist shifts, but the economic return depends on local scan demand.

SPECT/CT should benefit from targeted radionuclide therapy, where quantitative follow-up and dosimetry require more than planar scintigraphy. GE StarGuide GX, Mediso TheraMAX and Spectrum Dynamics VERITON-CT represent distinct hardware approaches. The pace of adoption depends on the number of centers delivering radioligand therapies, radiopharmacy availability and clinical reimbursement. Demand for compatible reconstruction and lesion-analysis software may rise even at sites that postpone replacing their entire camera fleet.

PET/MR will remain a smaller segment despite renewed product activity. Siemens Biograph One and United Imaging uPMR Zenith entered new regulatory markets in 2026, offering combined anatomical and functional imaging for selected oncology and neurology applications. MRI integration costs favor academic centers. Broader use requires evidence that combined examinations improve decisions versus separate scans.

Regional expansion should be strongest where hospitals can pair equipment funding with tracer distribution and specialist training. United Imaging reported 2025 projects in Australia and India, while German academic centers added long-field PET/CT and quantitative SPECT/CT during 2025–2026. Risks include deferred capital spending, uneven reimbursement and isotope shortages. Upside comes from better throughput, broader radiopharmaceutical indications and software that makes quantitative studies more repeatable.

Coverage addresses hybrid imaging manufacturers, integrated scanner configurations, nuclear medicine purchasing institutions and clinical applications across the global equipment market.